A Review of Resection and Surgical Ablation for Primary and Secondary Liver Cancers

Abstract

The surgical management of primary and secondary liver tumors is constantly evolving. Patient selection, particularly with regard to determining resectability, is vital to the success of programs directed toward invasive treatments of liver tumors. Particular attention should be paid toward determining whether patients are best served with surgical resection or ablative therapies. A multidisciplinary approach is necessary to provide optimal care to patients with liver malignancy.

Keywords

liver resection - liver ablation - liver-directed therapy - surgery - hepatocellular carcinoma - liver metastases

Publikationsverlauf

Artikel online veröffentlicht:
24. Januar 2024

• References

• 1 Clavien PA, Petrowsky H, DeOliveira ML, Graf R. Strategies for safer liver surgery and partial liver transplantation. N Engl J Med 2007; 356 (15) 1545-1559
• 2 Couinaud C. Lobes et segments hépatiques: notes sur l'architecture anatomiques et chirurgicale du foie [Liver lobes and segments: notes on the anatomical architecture and surgery of the liver ]. Presse Med (1893). 1954; 62 (33) 709-712
• 3 Strasberg SM, Belghiti J, Clavien PA. et al. The Brisbane 2000 terminology of liver anatomy and resections. HPB (Oxford) 2000; 2 (03) 333-339
• 4 Wakabayashi G, Cherqui D, Geller DA. et al. The Tokyo 2020 terminology of liver anatomy and resections: updates of the Brisbane 2000 system. J Hepatobiliary Pancreat Sci 2022; 29 (01) 6-15
• 5 Pulitano C, Crawford M, Joseph D, Aldrighetti L, Sandroussi C. Preoperative assessment of postoperative liver function: the importance of residual liver volume. J Surg Oncol 2014; 110 (04) 445-450
• 6 Abdalla EK, Barnett CC, Doherty D, Curley SA, Vauthey JN. Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch Surg 2002; 137 (06) 675-680 , discussion 680–681
• 7 Abdalla EK, Adam R, Bilchik AJ, Jaeck D, Vauthey JN, Mahvi D. Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 2006; 13 (10) 1271-1280
• 8 Abdalla EK. Portal vein embolization (prior to major hepatectomy) effects on regeneration, resectability, and outcome. J Surg Oncol 2010; 102 (08) 960-967
• 9 Truant S, Baillet C, Gnemmi V. et al. The impact of modern chemotherapy and chemotherapy-associated liver injuries (CALI) on liver function: value of 99mTc-labelled-mebrofenin SPECT-hepatobiliary scintigraphy. Ann Surg Oncol 2021; 28 (04) 1959-1969
• 10 Wang LJ, Yan XL, Li J, Wang K, Xing BC. Indocyanine green clearance test for the preoperative assessment of chemotherapy-related hepatic injury in patients with colorectal liver metastasis. Cancer Manag Res 2020; 12: 3237-3245
• 11 Chapelle T, Op De Beeck B, Huyghe I. et al. Future remnant liver function estimated by combining liver volumetry on magnetic resonance imaging with total liver function on (99m)Tc-mebrofenin hepatobiliary scintigraphy: can this tool predict post-hepatectomy liver failure?. HPB (Oxford) 2016; 18 (06) 494-503
• 12 Primavesi F, Maglione M, Cipriani F. et al. E-AHPBA-ESSO-ESSR Innsbruck consensus guidelines for preoperative liver function assessment before hepatectomy. Br J Surg 2023; 110 (10) 1331-1347
• 13 Currie BM, Hoteit MA, Ben-Josef E, Nadolski GJ, Soulen MC. Radioembolization-induced chronic hepatotoxicity: a single-center cohort analysis. J Vasc Interv Radiol 2019; 30 (12) 1915-1923
• 14 Kim DY, Park BJ, Kim YH. et al. Radioembolization with yttrium-90 resin microspheres in hepatocellular carcinoma: a multicenter prospective study. Am J Clin Oncol 2015; 38 (05) 495-501
• 15 Hamoui N, Ryu RK. Hepatic radioembolization complicated by fulminant hepatic failure. Semin Intervent Radiol 2011; 28 (02) 246-251
• 16 Khan A, Sayles HR, Dhir M. Liver resection after Y-90 radioembolization: a systematic review and meta-analysis of perioperative morbidity and mortality. HPB (Oxford) 2022; 24 (02) 152-160
• 17 Shindoh J, Tzeng CWD, Aloia TA. et al. Optimal future liver remnant in patients treated with extensive preoperative chemotherapy for colorectal liver metastases. Ann Surg Oncol 2013; 20 (08) 2493-2500
• 18 Robinson SM, Wilson CH, Burt AD, Manas DM, White SA. Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis. Ann Surg Oncol 2012; 19 (13) 4287-4299
• 19 LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2012 . Irinotecan. Published online April 27, 2018. Accessed October 19, 2023 at: https://www.ncbi.nlm.nih.gov/books/
• 20 Han J, Zhang J, Zhang C. Irinotecan-induced steatohepatitis: current insights. Front Oncol 2021; 11: 754891
• 21 Gaba RC, Lewandowski RJ, Kulik LM. et al. Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization. Ann Surg Oncol 2009; 16 (06) 1587-1596
• 22 Shindoh J, Truty MJ, Aloia TA. et al. Kinetic growth rate after portal vein embolization predicts posthepatectomy outcomes: toward zero liver-related mortality in patients with colorectal liver metastases and small future liver remnant. J Am Coll Surg 2013; 216 (02) 201-209
• 23 You Y, Heo JS, Shin SH. et al. Optimal timing of portal vein embolization (PVE) after preoperative biliary drainage for hilar cholangiocarcinoma. HPB (Oxford) 2022; 24 (05) 635-644
• 24 Creasy JM, Sadot E, Koerkamp BG. et al. Actual 10-year survival after hepatic resection of colorectal liver metastases: what factors preclude cure?. Surgery 2018; 163 (06) 1238-1244
• 25 Leung U, Kuk D, D'Angelica MI. et al. Long-term outcomes following microwave ablation for liver malignancies. Br J Surg 2015; 102 (01) 85-91
• 26 Lee DH, Kim JW, Lee JM. et al. Laparoscopic liver resection versus percutaneous radiofrequency ablation for small single nodular hepatocellular carcinoma: comparison of treatment outcomes. Liver Cancer 2021; 10 (01) 25-37
• 27 Groeschl RT, Gamblin TC, Turaga KK. Ablation for hepatocellular carcinoma: validating the 3-cm breakpoint. Ann Surg Oncol 2013; 20 (11) 3591-3595
• 28 Groeschl RT, Pilgrim CHC, Hanna EM. et al. Microwave ablation for hepatic malignancies: a multiinstitutional analysis. Ann Surg 2014; 259 (06) 1195-1200
• 29 Puijk RS, Ruarus AH, Vroomen LGPH. et al; COLLISION Trial Group. Colorectal liver metastases: surgery versus thermal ablation (COLLISION) - a phase III single-blind prospective randomized controlled trial. BMC Cancer 2018; 18 (01) 821
• 30 Tinguely P, Ruiter SJS, Engstrand J. et al. A prospective multicentre trial on survival after Microwave Ablation VErsus Resection for Resectable Colorectal liver metastases (MAVERRIC). Eur J Cancer 2023; 187: 65-76
• 31 White MJ, Nelson AT, Wothe J. et al. Feasibility of laparoscopic microwave ablation of caudate tumors: a case series. J Surg Case Rep 2023; 2023 (08) rjad478
• 32 Altman AM, Coughlan A, Shukla DM. et al. Minimally invasive microwave ablation provides excellent long-term outcomes for otherwise inaccessible hepatocellular cancer. J Surg Oncol 2020; 121 (08) 1218-1224
• 33 Lin MX, Ye JY, Tian WS. et al. Risk factors for bile duct injury after percutaneous thermal ablation of malignant liver tumors: a retrospective case-control study. Dig Dis Sci 2017; 62 (04) 1086-1094
• 34 Huang JW, Hernandez-Alejandro R, Croome KP. et al. Surgical vs percutaneous radiofrequency ablation for hepatocellular carcinoma in dangerous locations. World J Gastroenterol 2011; 17 (01) 123-129
• 35 Wada Y, Takami Y, Ryu T. et al. Predictive factors for local recurrence after intraoperative microwave ablation for colorectal liver metastases. Cancers (Basel) 2022; 15 (01) 122
• 36 McEachron KR, Ankeny JS, Robbins A. et al. Surgical microwave ablation of otherwise non-resectable colorectal cancer liver metastases: expanding opportunities for long term survival. Surg Oncol 2021; 36: 61-64
• 37 Huang X, Liu Y, Xu L. et al. Meta-analysis of percutaneous vs. surgical approaches radiofrequency ablation in hepatocellular carcinoma. Front Surg 2022; 8: 788771
• 38 Cassera MA, Potter KW, Ujiki MB, Swanström LL, Hansen PD. Computed tomography (CT)-guided versus laparoscopic radiofrequency ablation: a single-institution comparison of morbidity rates and hospital costs. Surg Endosc 2011; 25 (04) 1088-1095
• 39 Puijk RS, Dijkstra M, van den Bemd BAT. et al. Improved outcomes of thermal ablation for colorectal liver metastases: a 10-year analysis from the Prospective Amsterdam CORE Registry (AmCORE). Cardiovasc Intervent Radiol 2022; 45 (08) 1074-1089
• 40 Menahem B, Lubrano J, Duvoux C. et al. Liver transplantation versus liver resection for hepatocellular carcinoma in intention to treat: an attempt to perform an ideal meta-analysis. Liver Transpl 2017; 23 (06) 836-844
• 41 Seshadri RM, Besur S, Niemeyer DJ. et al. Survival analysis of patients with stage I and II hepatocellular carcinoma after a liver transplantation or liver resection. HPB (Oxford) 2014; 16 (12) 1102-1109
• 42 Koh JH, Tan DJH, Ong Y. et al. Liver resection versus liver transplantation for hepatocellular carcinoma within Milan criteria: a meta-analysis of 18,421 patients. Hepatobiliary Surg Nutr 2022; 11 (01) 78-93
• 43 Mahmud N. Selection for liver transplantation: indications and evaluation. Curr Hepatol Rep 2020; 19 (03) 203-212
• 44 Berry K, Ioannou GN. Comparison of liver transplant-related survival benefit in patients with versus without hepatocellular carcinoma in the United States. Gastroenterology 2015; 149 (03) 669-680 , quiz e15–e16
• 45 Ruf AE, Kremers WK, Chavez LL, Descalzi VI, Podesta LG, Villamil FG. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl 2005; 11 (03) 336-343
• 46 Kim WR, Biggins SW, Kremers WK. et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 2008; 359 (10) 1018-1026
• 47 Mazzaferro V, Regalia E, Doci R. et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334 (11) 693-699
• 48 Child CG, Turcotte JG. Surgery and portal hypertension. Major Probl Clin Surg 1964; 1: 1-85
• 49 Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60 (08) 646-649
• 50 Schroeder RA, Marroquin CE, Bute BP, Khuri S, Henderson WG, Kuo PC. Predictive indices of morbidity and mortality after liver resection. Ann Surg 2006; 243 (03) 373-379
• 51 Hong SK, Lee KW, Hong SY. et al. Efficacy of liver resection for single large hepatocellular carcinoma in Child-Pugh A cirrhosis: analysis of a nationwide cancer registry database. Front Oncol 2021; 11: 674603
• 52 Reig M, Forner A, Rimola J. et al. BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. J Hepatol 2022; 76 (03) 681-693
• 53 Trevisani F, Frigerio M, Santi V, Grignaschi A, Bernardi M. Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal. Dig Liver Dis 2010; 42 (05) 341-347
• 54 Desai A, Sandhu S, Lai JP, Sandhu DS. Hepatocellular carcinoma in non-cirrhotic liver: a comprehensive review. World J Hepatol 2019; 11 (01) 1-18
• 55 Penzkofer L, Mittler J, Heinrich S. et al. Outcome after resection for hepatocellular carcinoma in noncirrhotic liver - a single centre study. J Clin Med 2022; 11 (19) 5802
• 56 Groot Koerkamp B, Wiggers JK, Allen PJ. et al. Recurrence rate and pattern of perihilar cholangiocarcinoma after curative intent resection. J Am Coll Surg 2015; 221 (06) 1041-1049
• 57 Nooijen LE, Franssen S, Buis CI. et al. Long-term follow-up of a randomized trial of biliary drainage in perihilar cholangiocarcinoma. HPB (Oxford) 2023; 25 (02) 210-217
• 58 Palavecino M, Abdalla EK, Madoff DC, Vauthey JN. Portal vein embolization in hilar cholangiocarcinoma. Surg Oncol Clin N Am 2009; 18 (02) 257-267 , viii
• 59 Olthof PB, Aldrighetti L, Alikhanov R. et al; Perihilar Cholangiocarcinoma Collaboration Group. Portal vein embolization is associated with reduced liver failure and mortality in high-risk resections for perihilar cholangiocarcinoma. Ann Surg Oncol 2020; 27 (07) 2311-2318
• 60 Rosen CB, Heimbach JK, Gores GJ. Surgery for cholangiocarcinoma: the role of liver transplantation. HPB (Oxford) 2008; 10 (03) 186-189
• 61 Rea DJ, Heimbach JK, Rosen CB. et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 2005; 242 (03) 451-458 , discussion 458–461
• 62 Oh DY, He AR, Qin S. et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 2022; 1 (08)
• 63 Akateh C, Ejaz AM, Pawlik TM, Cloyd JM. Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma. World J Hepatol 2020; 12 (10) 693-708
• 64 Rahbari NN, Biondo S, Feißt M. et al. Randomized clinical trial on resection of the primary tumor versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases. J Clin Oncol 2022; 40 (17) LBA3507-LBA3507
• 65 Kanemitsu Y, Shitara K, Mizusawa J. et al; JCOG Colorectal Cancer Study Group. Primary tumor resection plus chemotherapy versus chemotherapy alone for colorectal cancer patients with asymptomatic, synchronous unresectable metastases (JCOG1007; iPACS): a randomized clinical trial. J Clin Oncol 2021; 39 (10) 1098-1107
• 66 Feo L, Polcino M, Nash GM. Resection of the primary tumor in stage IV colorectal cancer: When is it necessary?. Surg Clin North Am 2017; 97 (03) 657-669
• 67 Helling TS, Martin M. Cause of death from liver metastases in colorectal cancer. Ann Surg Oncol 2014; 21 (02) 501-506
• 68 Srouji R, Narayan R, Boerner T. et al. Addition of adjuvant hepatic artery infusion to systemic chemotherapy following resection of colorectal liver metastases is associated with reduced liver-related mortality. J Surg Oncol 2020; 121 (08) 1314-1319
• 69 Nordlinger B, Sorbye H, Glimelius B. et al; EORTC Gastro-Intestinal Tract Cancer Group, Cancer Research UK, Arbeitsgruppe Lebermetastasen und–tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO), Australasian Gastro-Intestinal Trials Group (AGITG), Fédération Francophone de Cancérologie Digestive (FFCD). Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 2013; 14 (12) 1208-1215
• 70 Kanemitsu Y, Shimizu Y, Mizusawa J. et al; JCOG Colorectal Cancer Study Group. Hepatectomy followed by mFOLFOX6 versus hepatectomy alone for liver-only metastatic colorectal cancer (JCOG0603): a phase II or III randomized controlled trial. J Clin Oncol 2021; 39 (34) 3789-3799
• 71 Engstrand J, Sterner J, Hasselgren K, Stromberg C, Sturesson C. Treatment intention and outcome in patients with simultaneously diagnosed liver and lung metastases from colorectal cancer. Eur J Surg Oncol 2022; 48 (08) 1799-1806
• 72 Tran TB, Worhunsky DJ, Spain DA. et al. The significance of underlying cardiac comorbidity on major adverse cardiac events after major liver resection. HPB (Oxford) 2016; 18 (09) 742-747
• 73 Hallet J, Tillman B, Zuckerman J. et al; Members of the Recovery after Surgical Therapy for Older Adults Research–Cancer (RESTORE-Cancer) Group. Association between frailty and time alive and at home after cancer surgery among older adults: a population-based analysis. J Natl Compr Canc Netw 2022; 20 (11) 1223-1232.e8
• 74 Liu TS, Shen QH, Zhou XY. et al. Application of controlled low central venous pressure during hepatectomy: a systematic review and meta-analysis. J Clin Anesth 2021; 75: 110467
• 75 Melendez JA, Arslan V, Fischer ME. et al. Perioperative outcomes of major hepatic resections under low central venous pressure anesthesia: blood loss, blood transfusion, and the risk of postoperative renal dysfunction. J Am Coll Surg 1998; 187 (06) 620-625
• 76 Yu L, Sun H, Jin H, Tan H. The effect of low central venous pressure on hepatic surgical field bleeding and serum lactate in patients undergoing partial hepatectomy: a prospective randomized controlled trial. BMC Surg 2020; 20 (01) 25
• 77 O'Connor DC, Seier K, Gonen M. et al. Invasive central venous monitoring during hepatic resection: unnecessary for most patients. HPB (Oxford) 2020; 22 (12) 1732-1737
• 78 Jongerius IM, Mungroop TH, Uz Z. et al. Goal-directed fluid therapy vs. low central venous pressure during major open liver resections (GALILEO): a surgeon- and patient-blinded randomized controlled trial. HPB (Oxford) 2021; 23 (10) 1578-1585
• 79 Ratti F, Cipriani F, Reineke R. et al. Intraoperative monitoring of stroke volume variation versus central venous pressure in laparoscopic liver surgery: a randomized prospective comparative trial. HPB (Oxford) 2016; 18 (02) 136-144
• 80 Yang Y, Liu F, Yu J. et al. Risk factor analysis of acute kidney injury after microwave ablation of hepatocellular carcinoma: a retrospective study. Front Oncol 2020; 10: 1408
• 81 Li D, Yu J, Han Z. et al. Risk factors of haemoglobinuria after microwave ablation of liver tumours. Clin Radiol 2018; 73 (11) 982.e9-982.e15
• 82 Joliat GR, Kobayashi K, Hasegawa K. et al. Guidelines for perioperative care for liver surgery: Enhanced Recovery After Surgery (ERAS) Society Recommendations 2022. World J Surg 2023; 47 (01) 11-34
• 83 Jin S, Fu Q, Wuyun G, Wuyun T. Management of post-hepatectomy complications. World J Gastroenterol 2013; 19 (44) 7983-7991
• 84 Sultana A, Brooke-Smith M, Ullah S. et al. Prospective evaluation of the International Study Group for Liver Surgery definition of post hepatectomy liver failure after liver resection: an international multicentre study. HPB (Oxford) 2018; 20 (05) 462-469
• 85 Lee KF, Lo EYJ, Wong KKC. et al. Acute kidney injury following hepatectomy and its impact on long-term survival for patients with hepatocellular carcinoma. BJS Open 2021; 5 (05) 77
• 86 Rahbari NN, Garden OJ, Padbury R. et al. Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery 2011; 149 (05) 713-724
• 87 Søreide JA, Deshpande R. Post hepatectomy liver failure (PHLF) - recent advances in prevention and clinical management. Eur J Surg Oncol 2021; 47 (02) 216-224